氨酚双氢可待因片缓解痔疮术后疼痛的疗效观察  

Clinical observation of paracetamol and dihydrocodeine tartrate in treatment of pain after hemorrhoids operation

作　　者：阳宇[1] 王浪[2] 刘斌[2] 陈秋玲[1] 王大果[1] 

机构地区：[1]深圳市人民医院药剂科,广东深圳518020 [2]深圳市人民医院肛肠外科,广东深圳518020

出　　处：《中国现代医学杂志》2014年第31期100-102,共3页China Journal of Modern Medicine

摘　　要：目的探究氨酚双氢可待因片缓解痔疮术后疼痛的最佳给药方案。方法在该院肛肠外科住院患者384例,随机分为3组,3组均于术后3 h首次给药,观察组口服氨酚双氢可待因片2片后每隔6 h服2片;对照1组,首次给药后由病人自行感觉痛时再服用,一日不超过4次;对照2组首次口服曲马多缓释片1片,以后隔12 h服1片。比较临床疗效及不良反应。结果术后24 h疼痛强度值,对照1组与观察组、对照2组比较有明显差异(P<0.01)。不良反应发生率对照2组明显高于其他两组(P<0.01)。结论氨酚双氢可待因片用于痔疮术后止痛安全有效,且按时给药效果优于按需给药。[Objective ] The purpose of this study is to investigate the best dosing regimen of the compound tablets of paracetamol and dihydroeodeine tartrate to relieve the pain after hemorrhoids operation. [ Method ] 384 in- patients in the Department of Anus ＆ Intestine Surgery in our hospital were randomly divided into 3 groups. All three groups took the first medicine 3 hours after the surgery. The treatment group was treated with 2 tablets of paracetamol and dihydrocodeine tartrate tablet and then another 2 tablets every 6 hours. In contrast, the first control group didn＇t take any medicine after the first 2 tablets unless they feel pain. In addition, each patient can not take more than 4 times of the medicine within 24 hours. The second control group was treated with one tramadol sus- tained-release tablet for the first time and then another tablet after 12 hours. [Results] The first control group showed significant differences from the treatment group and second control group （P 〈0.01） in the 24 hours post-op- eration pain intensity value. The second control groups showed significantly higher incidence of adverse reaction than the other two groups （P 〈0.01）. [ Conclusion ] Paracetamol and dihydrocodeine tartrate tablets are safe and ef- fective in relieving post-operation pain for hemorrhoid. In addition, on-time delivery of the medicine can generate better outcomes than on-demand delivery of the medicine.

关 键 词：氨酚双氢可待因 痔疮术 疼痛 疗效观察 

分 类 号：R971.1[医药卫生—药品] R657.18[医药卫生—药学]